ARTHUR-D.-LITTLE
10.2.2020 14:55:09 CET | Business Wire | Press release
Arthur D. Little (ADL) has published its annual telecoms study, which highlights the need for greater reconfiguration in the global telecoms industry. Backed by client conversations, a global survey and interviews targeting investors, board members and senior executives of telecom operators, the study has revealed that inorganic growth options are a viable tool for operators to survive in the challenging telecoms market, with more than 90 percent of respondents agreeing. Over 60 percent of respondents also believe that the telecoms sector was facing disruption.
Technology and new business models are disintegrating and reconfiguring the typical telco delivery model, and this is leading to competition from a number of players along the telco value chain. In many situations, organic options beyond cost optimization are limited because the market is reaching maturity. At the same time, telco assets with varying risk and return profiles are becoming attractive to financial investors because telco assets can be mutualized under new ownership. If telcos do not succeed in aligning execution realities with investor expectations, shareholders are more likely to choose other options. One growing trend involves alternate investors that reconfigure or unbundle assets to extract better value.
To secure future growth, telcos will need to take advantage of mutualizing assets and creating focused platforms for growth, transformation and value creation, which is facilitated by disaggregating the telecom value chain. To do this, telcos must continue to make balanced investments between organic and inorganic options:
- Innovate the core based on local competition
- Build capabilities to prepare for the future, particularly digital transformation
- Secure reasons to be part of sustainable economics or drive in-market consolidation to reach sustainable economics
- Accelerate M&A in resulting focus areas beyond the core – i.e., B2C, as well as ICT, B2B2X and wholesale, to prepare for the future (to compensate for stagnating or declining core business).
“Telecom companies are lagging behind other industries in shareholder value creation, while wrestling to define optimal asset structures to prepare themselves for the future,” said Karim Taga, Managing Partner and Global Practice Leader TIME at Arthur D. Little . “Amid substantial competition from within and outside the industry, as well as sustained investment requirements, telcos must explore avenues for growth from both organic and inorganic perspectives in order to effectively embrace the future.”
“Embracing the future,” the newest edition of Arthur D. Little’s annual study on the telecoms industry, is based on more than 100 interviews with senior industry executives, investors and shareholders. It draws from a review of over 4,300 deals in relevant sectors and analysis of operator strategies across the globe.
To download the full report, visit: www.adlittle.com/EmbracingTheFuture .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200210005468/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
